Published on
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Published on
CHOP researchers have found that MN1 overexpression leads to stabilization of the BAF complex, which leads to overproduction of progenitor and stem cells.
Published on
The FDA has approved a treatment that targets ALK mutations in relapsed, refractory ALK-positive anaplastic large cell lymphoma.
Published on
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
CHOP’s Cancer Center helps families manage the extreme emotions elicited by a child’s cancer diagnosis through its world-class, comprehensive, innovative psychosocial services.
Published on
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
Published on
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Published on
The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.
Published on
A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.